Tags

Main Content

Top Content

Directory of Key words from the Journal and the latest article from it.

Testosterone surgeView Articles
ThalidomideView Articles
Therapy, adjuvantView Articles
Therapy, microwaveView Articles
Therapy, topicalView Articles
Third-generation cryotherapyView Articles

Volume 8, Supplement 2Review Articles

New Techniques and Management Options for Localized Prostate Cancer

16th International Prostate Cancer Update

Mack Roach IIIJoycelyn L Speight

Prostate cancer is diagnosed in younger men who want treatment that does not compromise their quality of life, take time away from work, or cause worrisome side effects. Laparoscopic radical prostatectomy, robot-assisted laparoscopic radical prostatectomy, and third-generation cryotherapy are modifications of previously used techniques in the treatment of prostate cancer and are presented in this article. Although some or all of the outcomes might be expected to change in the future, the urologic surgeon is left to select an approach, presumably on the basis of the experience, level of training, and care pathways at his or her institution. [Rev Urol. 2006;8(suppl 2):S22-S29]

Prostate cancerLaparoscopic radical prostatectomyThird-generation cryotherapy

Three-dimensional conformal radiation therapyView Articles
ThrombinView Articles

Volume 8, Number 3Review Articles

New Generation Tissue Sealants and Hemostatic Agents: Innovative Urologic Applications

Treatment Update

Dean G AssimosMichael A Traver

Control of blood loss during urologic surgery is paramount to the success of patient recovery. Hemostatic agents and tissue sealants are used routinely to prevent excess blood loss and in reconstruction during surgical repair. Some of the available products include thrombin sealant, fibrin glue, bovine serum/ albumin/glutaraldehyde, and gelatin matrix. Each of these agents differs in mechanism, cost, and application. Complications can include allergic reactions or thromboembolism and the risk of contracting bovine spongiform encephalitis or hepatitis. Many new hemostatic agents are being developed and approved. The benefits and risks of use of these agents versus conventional treatment need to be considered on a case-by-case basis by the surgeon. [Rev Urol. 2006;8(3):104-111]

HemostasisThrombin sealantsFibrin glueGelatin matrixThrombin

Thrombin sealantsView Articles

Volume 8, Number 3Review Articles

New Generation Tissue Sealants and Hemostatic Agents: Innovative Urologic Applications

Treatment Update

Dean G AssimosMichael A Traver

Control of blood loss during urologic surgery is paramount to the success of patient recovery. Hemostatic agents and tissue sealants are used routinely to prevent excess blood loss and in reconstruction during surgical repair. Some of the available products include thrombin sealant, fibrin glue, bovine serum/ albumin/glutaraldehyde, and gelatin matrix. Each of these agents differs in mechanism, cost, and application. Complications can include allergic reactions or thromboembolism and the risk of contracting bovine spongiform encephalitis or hepatitis. Many new hemostatic agents are being developed and approved. The benefits and risks of use of these agents versus conventional treatment need to be considered on a case-by-case basis by the surgeon. [Rev Urol. 2006;8(3):104-111]

HemostasisThrombin sealantsFibrin glueGelatin matrixThrombin

Thromboembolic eventsView Articles

Volume 12, Number 1Review Articles

Complications of Pelvic Lymphadenectomy: Do the Risks Outweigh the Benefits?

Treatment Review

Alan W PartinEdward M SchaefferStacy Loeb

The American Urological Association Best Practice Policy states that although pelvic lymph node dissection (PLND) is commonly done with radical prostatectomy, its morbidity must be considered, particularly in cases in which it offers little additional information. The benefits of PLND include more accurate staging and reassurance for the patient. In addition, PLND may be therapeutic for men with lymph node metastases and may result in long-term biochemical cure for selected node-positive patients. However, the incidence of node positivity is declining, and accordingly a greater number of lymphadenectomies must be performed to benefit 1 patient. In addition to the associated cost, PLND has the potential for morbidity, including lymphoceles, thromboembolic events, ureteral injury, and neurovascular injury. Patients and physicians should therefore assess the risk/benefit ratio associated with PLND on an individual basis to permit informed treatment decisions.[Rev Urol. 2010;12(1):20-24 doi:10.3909/riu0422]

Prostate cancerRadical prostatectomyPelvic lymph node dissectionUreteral injuryLymph node metastasesRisk to benefit ratioLymphoceleThromboembolic eventsVascular injuryNerve injury

ThrombusView Articles

Volume 19, Number 2Case Review

Transitional Cell Carcinoma of the Renal Pelvis With Venous Tumor Thrombus

Onkar SinghArun Jacob Phillip GeorgeJ Chandra SinghAntony Devasia

Renal cell carcinoma (RCC) is the most common malignancy that results in venous tumor thrombosis. Transitional cell carcinoma of the renal pelvis with renal or vena cava thrombus is extremely rare. Fewer than 40 cases have been reported. We report a similar case of a patient who underwent radical nephrectomy with a preoperative diagnosis of RCC. [Rev Urol. 2017;19(2):145–148 doi: 10.3909/riu0743] © 2017 MedReviews®, LLC

Urothelial carcinomaTransitional cell carcinomaKidneyInferior vena cavaThrombus

Tissue adhesionView Articles

Volume 17, Number 3Review Articles

Current Status of Hemostatic Agents and Sealants in Urologic Surgical Practice

Management Update

Sashi S KommuRobert McArthurAmr M EmaraUtsav D ReddyChristopher J AndersonNeil J BarberRaj A PersadChristopher G Eden

There has been a recent and near exponential increase in the use of hemostatic agents and sealants to supplement the rapidly evolving methods in the surgical management of urologic patients. This article reviews the use of hemostatic agents and sealants in current urologic practice. [Rev Urol. 2015;17(3):150-159 doi: 10.3909/riu0673] © 2015 MedReviews®, LLC

HemostasisTissue adhesionUrologic surgery

Tissue engineeringView Articles
Tissue sealantsView Articles
TMPRSS2-ERGView Articles

Volume 10, Number 2Meeting Reviews

Best of the 2008 AUA Annual Meeting

Meeting Review

Dean G AssimosDanil V MakarovAlan W PartinMichael B ChancellorJ Curtis NickelClaus G RoehrbornMichael K BrawerNaoki YoshimuraShing-Hwa Lu

Highlights from the 2008 Annual Meeting of the American Urological Association, May 17-22, 2008, Orlando, FL [Rev Urol. 2008;10(2):136-156]

Focal therapyProstate-specific antigenShock wave lithotripsyTumor markersOveractive bladder syndromeBlockersEarly prostate cancer antigenTMPRSS2-ERGCryotherapyUltrasound-estimated bladder weightElocalcitolLithium triboride laserStone formation

TMPRSS2ERGView Articles

Volume 11, Number 2Meeting Reviews

Best of the 2009 AUA Annual Meeting

Highlights From the 2009 Annual Meeting of the American Urological Association, April 25-30, 2009, Chicago, IL

Dean G AssimosEllen ShapiroAlan W PartinMichael B ChancellorStacy LoebJ Curtis NickelClaus G RoehrbornMichael K BrawerNaoki YoshimuraArie S BelldegrunB ShuchF Pouliot

Prostate cancer screeningObesityBenign prostatic hyperplasiaLower urinary tract symptomsVesicoureteral refluxNephrolithiasisStress urinary incontinenceInflammationSilodosinHormonal therapyTumor markersTMPRSS2ERG4-Kallikrein panelBotulinum toxin type AMale voiding dysfunctionBenign prostatic specific antigenRoux-en-Y gastric bypass surgeryGenitourinary pain indexUPOINT clinical phenotype systemNephron-sparing surgeryWatchful waitingLaparoscopy for adrenal cortical carcinomaPartial adrenalectomyUrethral traumaPediatric urethral strictureEnteric urologic surgery

TolterodineView Articles
Topical adjuvant chemo-immunotherapyView Articles

Volume 16, Number 1Review Articles

Nephron-sparing Management of Upper Tract Urothelial Carcinoma

Management Review

Tommaso BrancatoFrancesca Suriano

Upper tract urothelial carcinoma (UTUC) is a relatively rare tumor, but is characterized by high rates of recurrence, morbidity, and mortality. Choice of treatment modality is generally influenced by lesion size, grade, and focality. Radical nephroureterectomy with bladder cuff excision is the gold-standard management of UTUC, although an organ-sparing approach may be beneficial in selected patients. Conservative endoscopic management of UTUC in appropriate patients has a favorable impact on quality of life and health care costs when compared with patients who progress to dialysis-dependent renal failure. Careful ureteroscopic surveillance following endoscopic management of UTUC is essential. [Rev Urol. 2014;16(1):21-28 doi: 10.3909/riu0592] © 2014 MedReviews®, LLC

Upper tract urothelial carcinomaTumor gradeNephron-sparing endoscopic treatmentTopical adjuvant chemo-immunotherapyOncologic outcomes

ToremifeneView Articles
Torsade de pointesView Articles

Volume 10, Number 2Review Articles

The QT Interval and Selection of Alpha-Blockers for Benign Prostatic Hyperplasia

Treatment Update

Herbert LeporNorman E LeporLawrence A HillRichard G Trohman

The QT interval is the electrocardiographic manifestation of ventricular depolarization and repolarization. Drug-induced long QT syndrome is characterized by acquired, corrected QT (QTc) interval prolongation that is associated with increased risk of torsade de pointes. Every physician must recognize if the drugs he or she prescribes prolongs the QTc interval, especially if the drug is prescribed for a chronic condition in older patients who are on polypharmacy. The evolution of alpha-blockers for the treatment of benign prostatic hyperplasia has allowed the development of drugs that are easier to administer and better tolerated. Because alpha-blockers generally have equivalent efficacy, this class of drugs is typically differentiated by safety and side effects. Studies suggest that alpha-blockers may vary in regard to their effect on the QT interval, and, therefore, on their predisposition to cause potentially life-threatening ventricular arrhythmias. [Rev Urol. 2008;10(2):85-91]

BlockersBenign prostatichyperplasiaDrug-induced long QT syndromeTorsade de pointes

TorsionView Articles
Total colpocleisisView Articles
ToxicityView Articles
Tract seedlingView Articles

Volume 17, Number 4Case Review

Effectiveness of Antegrade Access in Bladder Tumors With Inaccessible Urethra

Abdul Rouf KhawajaTanveer Iqbal DarSajad MaikJavaid MagrayAshiq BhatArif Hameed BhatMohdSaleem WaniBaldev Singh Wazir

Inaccessible urethra with no retrograde endoscopic access due to multiple/diffuse strictures or multiple urethrocutaneous fistulas with acute urinary retention due to posturethral instrumentation (transurethral resection of bladder tumor [TURBT], or TURBT with transurethral resection of the prostate [TURP]), is a rare entity. Management of such a case with a bladder tumor for TURBT/surveillance cystoscopy poses a great challenge. The authors present 12 cases of bladder tumor with inaccessible urethra, 10 cases due to multiple strictures (post-TURBT and/or TURP), and 2 cases due to urethrocutaneous fistulas (post-TURBT), who presented to our emergency department with acute urinary retention. Emergent suprapubic catheterization was used as a temporary treatment method. [Rev Urol. 2015;17(4):241-245 doi: 10.3909/riu0677] © 2016 MedReviews®, LLC

Bladder tumorsSuprapubic cystostomyInaccessible urethraTract seedling

TrainingView Articles
Transdermal delivery systemView Articles
Transdermal drug deliveryView Articles
Transdermal therapyView Articles

Volume 11, Number 1Review Articles

The Evolution of Transdermal/Topical Overactive Bladder Therapy and Its Benefits Over Oral Therapy

Treatment Update

Scott MacDiarmid

Multiple antimuscarinic agents are available for the treatment of overactive bladder. Many of the agents have undergone reformulation in an attempt to improve patient adherence and drug tolerability. Oxybutynin evolved from an immediate-release pill to a once-daily oral preparation, and is now available as a transdermal patch and gel. This article discusses the clinical impact of oxybutynin reformulation and reviews the evolution and benefits of transdermal therapy.[Rev Urol. 2009;11(1):1-6]

OxybutyninReformulationTransdermal therapy

Transforming growth factor ß1View Articles
transfusionView Articles

Volume 19, Number 2Review Articles

The Use of Intraoperative Cell Salvage in Urologic Oncology

Surgical Update

Andres F CorreaMatthew C FerroniTimothy D LyonBenjamin J DaviesMichael C Ost

Intraoperative cell salvage (IOCS) has been used in urologic surgery for over 20 years to manage intraoperative blood loss and effectively minimize the need for allogenic blood transfusion. Concerns about viability of transfused erythrocytes and potential dissemination of malignant cells have been addressed in the urologic literature. We present a comprehensive review of the use of IOCS in urologic oncologic surgery. IOCS has been shown to preserve the integrity of erythrocytes during processing and effectively provides cell filtration to mitigate the risk of tumor dissemination. Its use is associated with reduction in the overall need for allogenic blood transfusion, which clinically reduces the risk of hypersensitivity reactions and disease transmission, and may have important implications on overall oncologic outcomes. In the context of a variety of urologic malignancies, including prostate, urothelial, and renal cancer, the use of IOCS appears to be safe, without risk of tumor spread leading to metastatic disease or differences in cancer-specific and overall survival. IOCS has been shown to be an effective intraoperative blood management strategy that appears safe for use in urologic oncology surgery. The ability to reduce the need for additional allogenic blood transfusion may have significant impact on immune-mediated oncologic outcomes. [Rev Urol. 2017;19(2):89–96 doi: 10.3909/riu0721] © 2017 MedReviews®, LLC

Urologic oncologyCell salvagetransfusion